CLINICAL TRIAL: A randomized, multinational, noninferiority, phase III trial to evaluate safety and efficacy of BF‐200 aminolaevulinic acid gel vs. methyl aminolaevulinate cream in the treatment of nonaggressive BCC with PDT https://t.co/zguhsjSDoO #BJD #D
A randomized, multi-national, non-inferiority, phase III trial to evaluate the safety and efficacy of BF-200 AL... https://t.co/Uw11XBliGE
RT @EurSocPhotobiol: New paper @BrJDermatol concludes that "Treatment of non-aggressive BCC with BF-200 ALA-PDT is highly effective and we…
New paper @BrJDermatol concludes that "Treatment of non-aggressive BCC with BF-200 ALA-PDT is highly effective and well tolerated with proven non-inferiority to MAL-PDT and demonstrates low recurrence rates after 1-year follow-up." https://t.co/brWPIFAWK